Enzymes naturally evolved across diverse and sometimes hostile environments. Their unique characteristics have powered many life science tools. For example, the thermostability of Taq Polymerase enabled DNA amplification through PCR, instituting a new era of genomics, and the activity of glucose oxidase was instrumental to the glucose meter marking the genesis of enzymatic biosensors. However, these natural enzymes have limitations and through protein engineering, evolved enzymes are unlocking next-generation tools.
Infectious disease testing at a global scale has highlighted the need for faster, more sensitive tools, such as RT-qPCR and isothermal amplification. More complex tools, such as DNA/RNA sequencing, epigenetic analysis, and more, require similar improvements. Your genomic tool of interest may be limited by the natural characteristics of the enzymes chosen. No longer, we are developing a proprietary portfolio of next-generation enzymes to meet the demands of tomorrow.
Partnerships: Alphazyme LLC, Roche
We are building a complete portfolio of next-generation enzymes for the synthesis and modification of DNA and RNA. Our portfolio includes single and double-stranded ligases, template-dependent and independent polymerases, nucleases, and others.
Partnership: Molecular Assemblies
Biosensors for human health and environmental monitoring are revolutionizing our quality of life. Enzymes enable the conversion of a biological signal to a digital one, thereby facilitating real-time decision-making. The directed evolution of biomolecules to operate as signaling devices allows you to detect what was previously undetectable.
Next-generation sequencing technologies have been applied in the field of molecular diagnostics, where they promise the potential for high specificity and sensitivity for detecting markers of disease. Widespread adoption of this evolving technology depends partly on the improvement of sample preparation workflows.
Join us on our journey.